
WHO Coordinated Scientific Advice Procedure

Mercedes Perez Gonzalez


Emerging Technologies, Research Prioritization & Support

Research for Health Department

Science Division



Where we fit in




THE SCIENCE DIVISION

Harnessing the power of science to achieve health for all.

Accelerating the impact of ethical research for people's health

RESEARCH FOR HEALTH DEPARTMENT



EMERGING TECHNOLOGIES, RESEARCH PRIORITIZATION AND SUPPORT


Optimizing and supporting Research and Development at WHO



Coordinated Scientific Advice



R&D processes at WHO




WHO Coordinated Scientific Advice (CSA)



WHO provides an **advice process** whereby **product developers** may approach WHO and obtain **joint advice** from **WHO Prequalification** and the **WHO Technical Department(s)**, in areas of unmet public health needs.



Goal:
To expedite access to appropriate, quality, safe, efficacious health products



PQ Prequalification
TD Technical Department

RFH Research for Health
SCI Science division

Objectives of the CSA



Provide advice to developers seeking to develop a health product in line with WHO's expressed unmet public health needs



Ensure **good understanding of WHO Policy and Prequalification** data needs and processes and to provide **feedback on specific areas** of content for manufacturer's development plans



Accelerate timelines for provision of data in line with Policy development and Prequalification requirements and improve the quality of submissions received for these processes

CSA - Key Principles



Voluntary



Confidential




Free of charge



Not binding



Impartial



Not a pre-evaluation of data,
Prequalification/Policy endorsement

CSA – Eligibility



New products, new/additional data on existing products



Potential significant public health value



Within scope of WHO PQ – with exceptions

Questions for CSA and timing for submission



Product developers are expected to submit specific questions related to the following aspects:

- Quality
- Non-Clinical
- Clinical/epidemiological




Optimal timing will vary depending on product type.

Clinical Development



Pilot CSA - Key steps and Timelines



Benefits of the WHO CSA



Standardized process: Submission Package template and explicit timelines



Single entry point for developers



Joint written advice from Technical Department(s) and Prequalification



Expected impact for future Policy / Prequalification applications in terms of quality of submissions and possibly timelines to both outcomes.

Predictability

Joint advice

**Optimized
resources use**

Pilot progress to date

14 CSA requests received



9 medicines



2 diagnostics



3 vaccines

12 requests accepted as eligible, 2 requests rejected

Average time during pilot: 85 days (~12 weeks > 10 weeks targeted time)

Evaluation through user survey feedback and targeted interviews identified a few areas for improvement.

CSA and other Scientific Advice procedures

Other existing SA procedures:

- EMA Scientific Advice (SA, protocol assistance, SA on medicine repurposing, parallel SA pilot with FDA, parallel consultations with HTA bodies etc.)
- FDA
- In the context of a scientific opinion: EUM4All, Swiss MAGHP scientific advice with/without involvement from WHO and/or National Regulatory Authorities of targeted countries
- Other NRAs, local procedures

Processes in which WHO is involved are not exclusive. Developers are requested to mention previous interactions with national/regional regulatory authorities when approaching WHO for a CSA.

WHO CSA is specifically designed to advise on WHO requirements and not intended to provide advice to meet other NRA requirements.

Thank you

For more information, please
contact:

ScientificAdvice@who.int



Or visit our [CSA website](#)



Mercedes Perez Gonzalez

perezgonzalezm@who.int